18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia

Launched by UNIVERSITY COLLEGE, LONDON · Apr 29, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a new way to help find hidden infections in patients with a serious condition called Staphylococcus aureus bacteraemia, which is when harmful bacteria are present in the blood. This condition can lead to severe health issues and even death, so it’s crucial for doctors to quickly identify where the infection is hiding in the body. The trial will compare the usual tests patients receive, like chest X-rays, with an additional advanced scan called a PET/CT scan to see if the PET/CT scan can find more hidden infection sources.

To participate in this trial, you must be an adult over 18 years old, have been diagnosed with S. aureus in your blood, and be currently receiving treatment in a hospital. If you join, you’ll be randomly assigned to either continue with the usual tests or receive the additional PET/CT scan as soon as possible. The study aims to see if this extra scan leads to better outcomes for patients by finding and treating hidden infections more effectively. Results from this trial could change how doctors approach this dangerous condition in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult (≥18 years of age)
• • Staphylococcus aureus complex grown from ≥1 blood culture
• • Symptoms of S. aureus bloodstream infection
• • Admitted to a participating hospital at the time of eligibility assessment . Agrees to PET/CT
• Exclusion Criteria:
• • Contraindication to PET/CT (including pregnancy/breast-feeding)
• • PET/CT in the last 7 days or already planned to occur in the next 7 days
• • Treating team deems enrolment in the study is not in the best interest of the patient
• • Treating team believes that death is imminent and inevitable
• • Patient is for end-of-life care and PET/CT is considered not appropriate